Reata Pharmaceuticals, Inc.

Edifire LLC

Reata Pharmaceuticals Holdings, LLC

Hanchett Entry Systems, Inc.

Abbvie Inc.

Encysive Pharmaceuticals, Inc.

Eosera, Inc.

Eric Anderson

Xin Jiang

Melean Visnick

Xiaofeng Liu

Daniel P Goepp

Gary Louis Bolton

Bradley W Caprathe

William Howard Roark

Chitase Lee

Christopher F Bender

Andrea Decker

Patrick Michael O'Brien

Robert M Kral, Jr

Marc Rudkowski

Deborah A Ferguson

Rolf Wagner

Wen Li

Allan C Krueger

Chengde Wu

Pamela L Donner

David J Grampovnik

Hui-Ju J Chen

Howard Robin Heyman

Jason P Shanley

Randall Shaffer

Michael J Rozema

Brian Dupre

Brett L Davis

Daxin Gao

Dagan Henderson

Haizhou Sun

Christopher Bender

Joe Griffin

Raymond J Kessler

Howard Heyman

Jason Shanley

Michael Rozema

Pamela Donner

David Grampovnik

Allan Krueger

William Roark

Bradley William Caprathe

Patrick M O'brien

This invention provides, but is not limited to, novel oleanolic acid derivatives having the formula: wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds, methods and intermediates useful for making the compounds, and methods of using the compounds and compositions.

Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17

The present invention relates generally to the compound:

2,2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereof

Disclosed herein are novel antioxidant inflammation modulators, including those of the formula: wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds. Methods and intermediates useful for making the compounds, and methods of using the compounds and compositions thereof are also provided.

Pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators

Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at c-17

Systems and methods for removal of human cerumen are provided. A composition for removal of cerumen includes at least one cerumenolytically acceptable active agent and an otologically acceptable vehicle. The cerumenolytically acceptable active agent may be an alpha-hydroxy acid (AHA). Exemplary AHA may include, but are not limited to, glycolic acid, tartronic acid, lactic acid, malic acid and any derivative or mixture thereof. The otologically acceptable vehicle may be sodium or potassium salts of bicarbonate aqueous buffer. Yet further, the otologically acceptable vehicle may contain sodium docusate. Cerumen may be removed and/or a cerumen impaction may be treated by administering to a patient in need thereof a composition comprising an AHA and an otologically acceptable vehicle.

Compositions and methods for cerumen removal

A novel and useful degauss circuit for use with electromagnetic door locks. The door lock circuit is configured to provide a constant current to the electromagnetic coil load. A pulse width modulation (PWM) controller varies the frequency and/or duty cycle to a switch in series with the coil. Coil current feedback is used to adjust the PWM frequency and/or duty cycle so as to maintain the current through the coil at a certain level to maintain a desired holding force on the door lock. A degauss circuit inline with the current flowing through the coil is provided. When triggered either in an uncontrolled or controlled manner, a series RLC circuit that includes the coil inductance and resistance causes ringing to occur whereby the coil current reverses direction with sufficient amplitude and duration to degauss the coil.

Degauss circuit for use in an electronically actuated door lock

Disclosed herein are novel C17-alkanediyl and alkenediyl derivatives of oleanolic acid, including those of the formula: wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds. Methods and intermediates useful for making the compounds, and methods of using the compounds, for example, as antioxidant inflammation modulators, and compositions thereof are also provided.

C17-alkanediyl and alkenediyl derivatives of oleanolic acid and methods of use thereof

Antioxidant Inflamation modulators: oleanolic acid derivatives with amino and other modifications at C-17

A REX activation detection and control module system configured to allow a REX device having at least four connectors to electrically connect with ACS devices having at least four connectors, while only connecting two wires to the REX device. The system comprises a first REX input/output device comprising two couplings and a second REX input/output device comprising at least four couplings. The system also comprises a current sense amplifier electrically connected to the first REX input/output device, the current sense amplifier configured to measure current from either the first REX input/output device. The system also comprises a microcontroller electrically connected to the current sense amplifier, the microcontroller configured to monitor the rolling average of the measured current output from the current sense amplifier. When the microcontroller detects an anomaly within the rolling average of the measured current, the microcontroller will activate the relay.

Request to exit two-wire control module

This invention provides novel compounds comprising the following anti-inflammatory pharmacore: wherein X, Rand Rare defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds, methods and intermediates useful for making the compounds, and methods of using the compounds and compositions.

Natural product analogs including an anti-inflammatory cyanoenone pharmacore and methods of use

Growing community of inventors

Southlake, TX, United States of America

Eric Anderson